Development of recombinant antibodies for diagnostic applications by protein engineering

Dissertation

Ari Hemminki

Research output: ThesisDissertationCollection of Articles

Abstract

Since the advent of hybridoma technology the exquisite specificity of monoclonal antibodies has been exploited for a number of applications in diagnostics, medicine and research. Today, monoclonal antibodies and binding fragments can also be produced by recombinant methods and this offers, in addition to efficient production, the means for convenient and rapid engineering of antibody fragments for different specific applications. In this work antibody engineering was used to increase the available lysine content of an anti-human alpha-fetoprotein (hAFP) Fab fragment and to improve its labelling properties for applications in which sensitive detection is essential. Monoclonal antibody derivatives binding testosterone (TES) with affinity and specificity sufficient for their use as reagents in immunoassays designed for the quantitative measurement of TES in clinical samples were also developed and characterised. Europium (Eu3+) chelates provide a nonradioactive alternative for sensitive labelling of antibodies for diagnostic immunoassays. Lysine residues at antibody surfaces are suitable targets for labelling by an isothiocyanate derivative of the chelate. In this work the labelling efficiency of a recombinant anti-hAFP Fab fragment was improved by increasing its lysine content by protein engineering. Molecular modelling was used to identify three light chain constant domain surface arginine residues which were mutated to lysine residues. The mutations did not influence the affinity of the lysine-enriched Fab fragment, and its labelling efficiency was found to be about 40 percent higher than that of the wild-type Fab fragment. With a low degree of labelling, the affinities of the two Fab fragments were identical and comparable to that of the original monoclonal anti-hAFP IgG. With higher degrees of labelling the affinities of both Fab fragments decreased more than that of the intact IgG since more lysine residues are available for labelling in the additional heavy chain constant domains of the larger molecule. A great number of small, rigid and hydrophobic steroid hormones, with very similar structures and containing only a few functional groups capable of direct interactions with antibodies, have remained as a major challenge for immunodiagnostics. The majority of commercially available diagnostic test kits for steroid hormones utilise polyclonal antibodies, not because of optimal performance and product quality, but because of the apparent lack of monoclonal antibodies fulfilling the clinical requirements. Semirandom mutagenesis of an existing monoclonal antibody combined with different phage display selection strategies was employed in the development of highly specified TES-binding recombinant antibodies. The optimisation of the CDR sequences and the CDR combination resulted in clones having an excellent overall binding profile. It was shown that many variant sequences of the original 3-C4F5 antibody can confer an antibody TES-binding specificity and affinity comparable to those of a rabbit polyclonal anti-testosterone antiserum currently used in a diagnostic immunoassay. To the best knowledge of this author the developed mutant Fab fragments of the 3-C4F5 antibody are the first steroid hormone-binding recombinant antibodies shown to work accurately over the whole physiological concentration range of clinical samples.
Original languageEnglish
QualificationDoctor Degree
Awarding Institution
  • University of Helsinki
Award date13 Nov 1998
Place of PublicationEspoo
Publisher
Print ISBNs951-38-5342-X
Electronic ISBNs951-38-5343-8
Publication statusPublished - 1998
MoE publication typeG5 Doctoral dissertation (article)

Fingerprint

Immunoglobulin Fab Fragments
Labeling
Antibodies
Lysine
Steroid hormones
Testosterone
Proteins
Monoclonal Antibodies
Diagnostic Reagent Kits
Immunoglobulin G
Europium
Derivatives
Immunoglobulin Fragments
Mutagenesis
Bacteriophages
Molecular modeling
Functional groups
Medicine
Arginine
Immune Sera

Keywords

  • antibodies
  • protein engineering
  • recombination (genetics)
  • lysine, labelling

Cite this

Hemminki, A. (1998). Development of recombinant antibodies for diagnostic applications by protein engineering: Dissertation. Espoo: VTT Technical Research Centre of Finland.
Hemminki, Ari. / Development of recombinant antibodies for diagnostic applications by protein engineering : Dissertation. Espoo : VTT Technical Research Centre of Finland, 1998. 110 p.
@phdthesis{8495c3c78a9546da9b963adb0232ab7a,
title = "Development of recombinant antibodies for diagnostic applications by protein engineering: Dissertation",
abstract = "Since the advent of hybridoma technology the exquisite specificity of monoclonal antibodies has been exploited for a number of applications in diagnostics, medicine and research. Today, monoclonal antibodies and binding fragments can also be produced by recombinant methods and this offers, in addition to efficient production, the means for convenient and rapid engineering of antibody fragments for different specific applications. In this work antibody engineering was used to increase the available lysine content of an anti-human alpha-fetoprotein (hAFP) Fab fragment and to improve its labelling properties for applications in which sensitive detection is essential. Monoclonal antibody derivatives binding testosterone (TES) with affinity and specificity sufficient for their use as reagents in immunoassays designed for the quantitative measurement of TES in clinical samples were also developed and characterised. Europium (Eu3+) chelates provide a nonradioactive alternative for sensitive labelling of antibodies for diagnostic immunoassays. Lysine residues at antibody surfaces are suitable targets for labelling by an isothiocyanate derivative of the chelate. In this work the labelling efficiency of a recombinant anti-hAFP Fab fragment was improved by increasing its lysine content by protein engineering. Molecular modelling was used to identify three light chain constant domain surface arginine residues which were mutated to lysine residues. The mutations did not influence the affinity of the lysine-enriched Fab fragment, and its labelling efficiency was found to be about 40 percent higher than that of the wild-type Fab fragment. With a low degree of labelling, the affinities of the two Fab fragments were identical and comparable to that of the original monoclonal anti-hAFP IgG. With higher degrees of labelling the affinities of both Fab fragments decreased more than that of the intact IgG since more lysine residues are available for labelling in the additional heavy chain constant domains of the larger molecule. A great number of small, rigid and hydrophobic steroid hormones, with very similar structures and containing only a few functional groups capable of direct interactions with antibodies, have remained as a major challenge for immunodiagnostics. The majority of commercially available diagnostic test kits for steroid hormones utilise polyclonal antibodies, not because of optimal performance and product quality, but because of the apparent lack of monoclonal antibodies fulfilling the clinical requirements. Semirandom mutagenesis of an existing monoclonal antibody combined with different phage display selection strategies was employed in the development of highly specified TES-binding recombinant antibodies. The optimisation of the CDR sequences and the CDR combination resulted in clones having an excellent overall binding profile. It was shown that many variant sequences of the original 3-C4F5 antibody can confer an antibody TES-binding specificity and affinity comparable to those of a rabbit polyclonal anti-testosterone antiserum currently used in a diagnostic immunoassay. To the best knowledge of this author the developed mutant Fab fragments of the 3-C4F5 antibody are the first steroid hormone-binding recombinant antibodies shown to work accurately over the whole physiological concentration range of clinical samples.",
keywords = "antibodies, protein engineering, recombination (genetics), lysine, labelling",
author = "Ari Hemminki",
year = "1998",
language = "English",
isbn = "951-38-5342-X",
series = "VTT Publications",
publisher = "VTT Technical Research Centre of Finland",
number = "365",
address = "Finland",
school = "University of Helsinki",

}

Development of recombinant antibodies for diagnostic applications by protein engineering : Dissertation. / Hemminki, Ari.

Espoo : VTT Technical Research Centre of Finland, 1998. 110 p.

Research output: ThesisDissertationCollection of Articles

TY - THES

T1 - Development of recombinant antibodies for diagnostic applications by protein engineering

T2 - Dissertation

AU - Hemminki, Ari

PY - 1998

Y1 - 1998

N2 - Since the advent of hybridoma technology the exquisite specificity of monoclonal antibodies has been exploited for a number of applications in diagnostics, medicine and research. Today, monoclonal antibodies and binding fragments can also be produced by recombinant methods and this offers, in addition to efficient production, the means for convenient and rapid engineering of antibody fragments for different specific applications. In this work antibody engineering was used to increase the available lysine content of an anti-human alpha-fetoprotein (hAFP) Fab fragment and to improve its labelling properties for applications in which sensitive detection is essential. Monoclonal antibody derivatives binding testosterone (TES) with affinity and specificity sufficient for their use as reagents in immunoassays designed for the quantitative measurement of TES in clinical samples were also developed and characterised. Europium (Eu3+) chelates provide a nonradioactive alternative for sensitive labelling of antibodies for diagnostic immunoassays. Lysine residues at antibody surfaces are suitable targets for labelling by an isothiocyanate derivative of the chelate. In this work the labelling efficiency of a recombinant anti-hAFP Fab fragment was improved by increasing its lysine content by protein engineering. Molecular modelling was used to identify three light chain constant domain surface arginine residues which were mutated to lysine residues. The mutations did not influence the affinity of the lysine-enriched Fab fragment, and its labelling efficiency was found to be about 40 percent higher than that of the wild-type Fab fragment. With a low degree of labelling, the affinities of the two Fab fragments were identical and comparable to that of the original monoclonal anti-hAFP IgG. With higher degrees of labelling the affinities of both Fab fragments decreased more than that of the intact IgG since more lysine residues are available for labelling in the additional heavy chain constant domains of the larger molecule. A great number of small, rigid and hydrophobic steroid hormones, with very similar structures and containing only a few functional groups capable of direct interactions with antibodies, have remained as a major challenge for immunodiagnostics. The majority of commercially available diagnostic test kits for steroid hormones utilise polyclonal antibodies, not because of optimal performance and product quality, but because of the apparent lack of monoclonal antibodies fulfilling the clinical requirements. Semirandom mutagenesis of an existing monoclonal antibody combined with different phage display selection strategies was employed in the development of highly specified TES-binding recombinant antibodies. The optimisation of the CDR sequences and the CDR combination resulted in clones having an excellent overall binding profile. It was shown that many variant sequences of the original 3-C4F5 antibody can confer an antibody TES-binding specificity and affinity comparable to those of a rabbit polyclonal anti-testosterone antiserum currently used in a diagnostic immunoassay. To the best knowledge of this author the developed mutant Fab fragments of the 3-C4F5 antibody are the first steroid hormone-binding recombinant antibodies shown to work accurately over the whole physiological concentration range of clinical samples.

AB - Since the advent of hybridoma technology the exquisite specificity of monoclonal antibodies has been exploited for a number of applications in diagnostics, medicine and research. Today, monoclonal antibodies and binding fragments can also be produced by recombinant methods and this offers, in addition to efficient production, the means for convenient and rapid engineering of antibody fragments for different specific applications. In this work antibody engineering was used to increase the available lysine content of an anti-human alpha-fetoprotein (hAFP) Fab fragment and to improve its labelling properties for applications in which sensitive detection is essential. Monoclonal antibody derivatives binding testosterone (TES) with affinity and specificity sufficient for their use as reagents in immunoassays designed for the quantitative measurement of TES in clinical samples were also developed and characterised. Europium (Eu3+) chelates provide a nonradioactive alternative for sensitive labelling of antibodies for diagnostic immunoassays. Lysine residues at antibody surfaces are suitable targets for labelling by an isothiocyanate derivative of the chelate. In this work the labelling efficiency of a recombinant anti-hAFP Fab fragment was improved by increasing its lysine content by protein engineering. Molecular modelling was used to identify three light chain constant domain surface arginine residues which were mutated to lysine residues. The mutations did not influence the affinity of the lysine-enriched Fab fragment, and its labelling efficiency was found to be about 40 percent higher than that of the wild-type Fab fragment. With a low degree of labelling, the affinities of the two Fab fragments were identical and comparable to that of the original monoclonal anti-hAFP IgG. With higher degrees of labelling the affinities of both Fab fragments decreased more than that of the intact IgG since more lysine residues are available for labelling in the additional heavy chain constant domains of the larger molecule. A great number of small, rigid and hydrophobic steroid hormones, with very similar structures and containing only a few functional groups capable of direct interactions with antibodies, have remained as a major challenge for immunodiagnostics. The majority of commercially available diagnostic test kits for steroid hormones utilise polyclonal antibodies, not because of optimal performance and product quality, but because of the apparent lack of monoclonal antibodies fulfilling the clinical requirements. Semirandom mutagenesis of an existing monoclonal antibody combined with different phage display selection strategies was employed in the development of highly specified TES-binding recombinant antibodies. The optimisation of the CDR sequences and the CDR combination resulted in clones having an excellent overall binding profile. It was shown that many variant sequences of the original 3-C4F5 antibody can confer an antibody TES-binding specificity and affinity comparable to those of a rabbit polyclonal anti-testosterone antiserum currently used in a diagnostic immunoassay. To the best knowledge of this author the developed mutant Fab fragments of the 3-C4F5 antibody are the first steroid hormone-binding recombinant antibodies shown to work accurately over the whole physiological concentration range of clinical samples.

KW - antibodies

KW - protein engineering

KW - recombination (genetics)

KW - lysine, labelling

M3 - Dissertation

SN - 951-38-5342-X

T3 - VTT Publications

PB - VTT Technical Research Centre of Finland

CY - Espoo

ER -

Hemminki A. Development of recombinant antibodies for diagnostic applications by protein engineering: Dissertation. Espoo: VTT Technical Research Centre of Finland, 1998. 110 p.